TAK 428

Drug Profile

TAK 428

Alternative Names: TK-428

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Takeda
  • Class
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diabetic neuropathies

Most Recent Events

  • 31 Oct 2013 Discontinued - Phase-II for Diabetic neuropathies in European Union (PO)
  • 31 Oct 2013 Discontinued - Phase-II for Diabetic neuropathies in USA (PO)
  • 29 Jul 2011 Phase-II development in Diabetic neuropathies is ongoing in the US and European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top